NCT00188695

Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide

A Pilot Study of MR Imaging With Ultra-small Superparamagnetic Iron Oxide for Pelvic Lymph Node Target Definition

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 61 (actual)
• Sponsor: University Health Network, Toronto · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to test whether or not a new contrast agent called Combidex, a contrast agent formulated from ultra-small superparamagnetic iron oxide (USPIO) improves the ability of Magnetic Resonance Imaging (MRI) to see lymph nodes in the pelvis. It might also help doctors tell whether or not cancer has spread to these lymph nodes. It might allow radiotherapy to be delivered more accurately.

Conditions

• Uterine Neoplasms
• Cervix Neoplasms
• Bladder Neoplasms
• Prostatic Neoplasms

Interventions

Type	Name	Description
PROCEDURE	MRI contrast agent Combidex (ferumoxtran-10)	Combidex as an MR-lymph node contrast agent for the detection of small lymph nodes and lymph metastases.

Timeline

• Start date: 2004-04-01
• Primary completion: 2006-06-01
• Completion: 2022-03-15
• First posted: 2005-09-16
• Last updated: 2022-10-07

Locations

1 site across 1 country: Canada